London, United Kingdom (PressExposure) December 09, 2009 -- Over the last decade there has been considerable evidence gathered, relating Patent Foramen Ovales (PFO) to migraines, cryptogenic stroke and decompression sickeness. There is an increased frequency of PFO in patients suffering from migraine- a frequency that almost parallels the presence of PFO in stroke. Currently, PFO closure is indicated for prevention of recurring stroke due to embolisms.
A string of clinical trials are now underway to establish the relation between PFO to migraine especially. A positive outcome establishing this relation in any of these trials will lead to an increased acceptance of PFO closure in patients with migraine, as opposed to temporary relief from drugs. The medical device industry is also bracing itself in hope of clinical trials like the PREMIUM, with a strong pipeline of improved PFO closure devices slated for release in the next couple of years. Aided by this pipeline and possible positive outcomes from the trials, the PFO market could position itself as one with high investment opportunities.
This analysis was taken from a research paper published by GlobalData, to download the full Research Paper for free, click below:
Access the latest Cardiovascular Devices analysis for free at http://www.researchviews.com
ResearchViews is your number one portal for industry related news, research, analysis and deals data. ResearchViews offers up to the minute content produced by an expert team of industry analysts.
All content on the site is free to view and allows users to keep up to date with the latest developments in their chosen industry. Free daily and weekly newsletters provide a snapshot of the major issues affecting the industry. The site also features a research store, providing the user with access to premium business intelligence from some of the world's leading market research publishers.